Although venture capitalists are the shepherds of large pools of risk capital, they really don’t like to have to take anything on faith. So it doesn’t help that non-invasive consumer glucose monitoring is often referred to as the "Holy Grail" in diabetes care. Does the Holy Grail really exist? After 10 to 15 years of investing in the field, investors have witnessed many failures and not a single success, and they have often found themselves supporting companies that even after 10 years remain in the development phase. Very few are believers any more.
That’s why, when GlucoLight Corp. was founded in 2003 to bring to market an optical platform for non-invasive glucose monitoring—specifically, optical coherence tomography—its founders decided to set themselves apart...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?